Author: Shuya Lu; Qi Zhou; Liping Huang; Qianling Shi; Siya Zhao; Zijun Wang; Weiguo Li; Yuyi Tang; Yanfang Ma; Xufei Luo; Toshio Fukuoka; Hyeong Sik Ahn; Myeong Soo Lee; Zhengxiu Luo; Enmei Liu; Yaolong Chen; Chenyan Zhou; Donghong Peng
Title: Effectiveness and Safety of Glucocorticoids to Treat COVID-19: A Rapid Review and Meta-Analysis Document date: 2020_4_22
ID: 935r7w01_46
Snippet: Heterogeneity in studies of mortality in SARS patients was reduced to 67.4% in the subgroup analysis of severe cases, and to 68.7% in the subgroup analysis of adults. Therefore, disease severity and age are probably the main sources of heterogeneity in the meta-analysis of mortality. We conducted a sensitivity analysis on the on the SARS mortality by omitting one study at a time. Two studies had a significant impact on the results of the meta-ana.....
Document: Heterogeneity in studies of mortality in SARS patients was reduced to 67.4% in the subgroup analysis of severe cases, and to 68.7% in the subgroup analysis of adults. Therefore, disease severity and age are probably the main sources of heterogeneity in the meta-analysis of mortality. We conducted a sensitivity analysis on the on the SARS mortality by omitting one study at a time. Two studies had a significant impact on the results of the meta-analysis (34, 35) ( Figure 11 ). The dosing of glucocorticoids was different in the study by Yam et al than in other studies, so the high heterogeneity in the meta-analysis on mortality may be at least partly caused by the different dosing (34).
Search related documents:
Co phrase search for related documents- age disease severity and disease severity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- age disease severity and high heterogeneity: 1
- age disease severity and meta analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- age disease severity and mortality analysis: 1, 2, 3, 4, 5, 6, 7
- age disease severity and SARS mortality: 1, 2, 3, 4, 5, 6
- age disease severity and SARS patient: 1, 2, 3
- age disease severity and sensitivity analysis: 1
- different dosing and glucocorticoid dosing: 1
- different dosing and meta analysis: 1, 2
- disease severity and high heterogeneity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- disease severity and main source: 1, 2, 3
- disease severity and meta analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- disease severity and meta mortality analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- disease severity and mortality analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- disease severity and SARS mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- disease severity and SARS patient: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- disease severity and SARS patient mortality: 1, 2, 3, 4
- disease severity and sensitivity analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- disease severity and sensitivity analysis conduct: 1
Co phrase search for related documents, hyperlinks ordered by date